BX2 Stock Overview
A commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
My Notes
Capture your thoughts, links and company narrative
BioXcel Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.32 |
| 52 Week High | US$3.76 |
| 52 Week Low | US$0.28 |
| Beta | -0.014 |
| 1 Month Change | 13.30% |
| 3 Month Change | -36.76% |
| 1 Year Change | -86.10% |
| 3 Year Change | -97.79% |
| 5 Year Change | -97.94% |
| Change since IPO | -95.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| BX2 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.7% | -1.9% | 3.5% |
| 1Y | -86.1% | -4.2% | 13.1% |
Return vs Industry: BX2 underperformed the German Biotechs industry which returned -3.8% over the past year.
Return vs Market: BX2 underperformed the German Market which returned 12.8% over the past year.
Price Volatility
| BX2 volatility | |
|---|---|
| BX2 Average Weekly Movement | 19.3% |
| Biotechs Industry Average Movement | 6.2% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.5% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BX2's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: BX2's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 74 | Vimal Mehta | www.bioxceltherapeutics.com |
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
BioXcel Therapeutics, Inc. Fundamentals Summary
| BX2 fundamental statistics | |
|---|---|
| Market cap | €16.42m |
| Earnings (TTM) | -€68.27m |
| Revenue (TTM) | €2.19m |
7.5x
P/S Ratio-0.2x
P/E RatioIs BX2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BX2 income statement (TTM) | |
|---|---|
| Revenue | US$2.28m |
| Cost of Revenue | US$2.03m |
| Gross Profit | US$251.00k |
| Other Expenses | US$71.25m |
| Earnings | -US$71.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | 11.03% |
| Net Profit Margin | -3,119.33% |
| Debt/Equity Ratio | -122.0% |
How did BX2 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 16:17 |
| End of Day Share Price | 2025/01/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
BioXcel Therapeutics, Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Anita Dushyanth | Berenberg |
| Guyn Kim | BMO Capital Markets Equity Research |
| Alec Stranahan | BofA Global Research |